Upstream commences testing of the FAST-TRAC cohort
The journey towards fully developing a diagnostic for people who fit the troponin grey zone is now one step closer, with testing starting on the FAST-TRAC cohort.
This cohort includes 1,500 chest pain patients from the US and Switzerland who presented to the emergency department. The aim of this testing phase is to validate Upstream’s diagnostic technology in rapidly and accurately triaging chest-pain patients who fall into a grey-zone with existing troponin assays.
Detecting at-risk heart attack patients, a step closer with $2m investment
Upstream Medical Technologies, a leading deep-tech company focused on developing innovative solutions for heart disease, announced today that it has closed a significant capital round to further advance its frontline diagnostic tests for cardiac diseases.
Upstream commences testing Marker C on the APACE cohort
The next phase of development is now underway, with the commencement of testing Marker C on the APACE cohort.